SARS Nucleocapsid antibody |
10R-10470 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
Human IgG antibody Laboratories manufactures the splke proteinand nucleocapsid proteins in sars-co-2 reagents distributed by Genprice. The Splke Proteinand Nucleocapsid Proteins In Sars-Co-2 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Splke products are available in stock. Specificity: Splke Category: Proteinand Group: Nucleocapsid Proteins
SARS-CoV-2 Nucleocapsid Peptide |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (IN) SARS-CoV-2 Nucleocapsid peptide |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS Nucleocapsid Recombinant Protein |
ProSci |
0.1 mL |
EUR 752.1 |
Description: The nucleocapsid (N) protein of SARS-coronavirus (SARS-CoV) is the key protein for the formation of the helical nucleocapsid during virion assembly. The nucleocapsid (N) protein of SARS-CoV enters the host cell together with the viral RNA and interferes with several cellular processes. Some of these processes involve interactions between SARS-CoV N protein and host- cell proteins. It has also been demonstrated that the SARS-CoV N protein can bind to DNA in vitro. These interactions might have a role in the pathology of SARS. The N protein may be of potential value in vaccine development for specific prophylaxis and treatment against SARS. |
SARS CoV Nucleocapsid Protein |
Abbexa |
1 mg |
EUR 2247.6 |
|
Nucleocapsid Proteins information
SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
97-085 |
ProSci |
0.1 mg |
EUR 789.9 |
Description: Nucleocapsid protein is a most abundant protein of coronavirus. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. While screening for ADP-ribosylated proteins during coronavirus (CoV) infection, we identified as the viral nucleocapsid (N) protein. Novel post-translation modification of the CoV N protein that may play a regulatory role for this important structural protein. The array of diverse functional activities accommodated in the hantaviral N protein goes far beyond to be a static structural protein and makes it an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. |
SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
92-728 |
ProSci |
1 mg |
EUR 1023 |
Description: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. |
SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
10-306 |
ProSci |
0.1 mg |
EUR 632.4 |
Description: SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
10-410 |
ProSci |
0.1 mg |
EUR 651.3 |
Description: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. |
SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein |
10-434 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. |
Nucleocapsid Protein (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2) |
100986 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end). This protein corresponds to SARS-CoV-2 Variant B.1.1.7 originally discovered in the United Kingdom, and contains mutations D3L, R203K, G204R, and S235F. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Nucleocapsid Protein (P.1 Variant), Avi-His-Tag (SARS-CoV-2) |
100987 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end), plus a C-terminal Avi-tag™ and a C-terminal His-tag. This protein corresponds to SARS-CoV-2 Variant P.1 originally discovered in Brazil and contains the mutation P80R. |
SARS Nucleocapsid antibody |
10R-10470 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS Nucleocapsid antibody |
10R-10471 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS Nucleocapsid Antibody |
20-abx137185 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2364.00
|
|
|
SARS Nucleocapsid Antibody |
20-abx137201 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
Nucleocapsid Protein, Avi-His-tag, Biotin-Labeled (SARS-CoV-2) |
100779-1 |
BPS Bioscience |
25 µg |
EUR 295 |
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-His-Tag™ technology. Biotinylation is confirmed to be ≥90% |
Nucleocapsid Protein, Avi-His-tag, Biotin-Labeled (SARS-CoV-2) |
100779-2 |
BPS Bioscience |
50 µg |
EUR 435 |
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-His-Tag™ technology. Biotinylation is confirmed to be ≥90% |
Nucleocapsid Protein, Avi-His-tag, Biotin-Labeled (SARS-CoV-2) |
100779-3 |
BPS Bioscience |
200 µg |
EUR 1370 |
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-His-Tag™ technology. Biotinylation is confirmed to be ≥90% |
SARS Coronavirus Nucleocapsid Core Recombinant protein |
39-121 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
Human Chimeric SARS-CoV-2 Nucleocapsid Protein Antibody (2019-nCov) |
R20480-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
SARS-CoV-2 (COVID-19) Nucleocapsid (N) Recombinant Protein |
10-080 |
ProSci |
0.1 mg |
EUR 619.8 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. The NTD of SARS-CoV-2 does not bind to ACE2 6, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties 7 and might play a role in the conformational change of S2 required for membrane fusion 8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients 9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV 10. |